Skip to main content
. 2016 Mar 18;7(17):23715–23729. doi: 10.18632/oncotarget.8173

Table 4. FL5.12 EML4-ALK mutant IC50s.

FL5.12 EML4-ALK
WT I1171S F1174L R1192P T1151M G1269A
IC50 Fold Change IC50 Fold Change IC50 Fold Change IC50 Fold Change IC50 Fold Change IC50 Fold Change
TKI Crizotinib 70.59 1 260.38 3.7 68.14 0.97 86.27 1.25 89.07 1.27 395.2 5.62
Ceritnib 9.6 1 64.69 6.79 16.86 1.76 16.96 1.79 24.24 2.53 14.57 1.52
Alectinib 3.46 1 224.28 64.98 3.35 0.98 2.55 0.70 3.00 0.87 40.09 11.6
AP26113 4.13 1 24.87 6.09 5.79 1.42 2.7 0.66 3.81 0.93 4.4 1.08
ASP3026 42.21 1 245.13 5.83 110.97 2.63 90.59 2.11 105.73 2.51 71.79 1.71
AZD3463 16.79 1 38.27 2.28 15.83 0.94 10.16 0.59 18.99 1.13 11.62 0.69